(Q37153622)

2 July 2019

review article

1 reference

title

ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer (English)

1 reference

2 July 2019

1 reference

David F Stern

1

1 reference

2 July 2019

language of work or name

1 reference

3 May 2008

1 reference

2 July 2019

Journal of Mammary Gland Biology and Neoplasia

published in

1 reference

2 July 2019

volume

13

1 reference

2 July 2019

issue

2

1 reference

2 July 2019

page(s)

215-223

1 reference

2 July 2019

https://scigraph.springernature.com/pub.10.1007/s10911-008-9083-7

exact match

0 references

cites work

p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10911-008-9083-7

The cellular response to neuregulins is governed by complex interactions of the erbB receptor family

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10911-008-9083-7

Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status

21 January 2018

1 reference

12 December 2020

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

1 reference

12 December 2020

Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer

1 reference

12 December 2020

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients

1 reference

12 December 2020

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

1 reference

12 December 2020

Key stages in mammary gland development: the cues that regulate ductal branching morphogenesis

1 reference

12 December 2020

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

12 December 2020

Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer

1 reference

12 December 2020

WW domain-containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function

1 reference

12 December 2020

Secretase-dependent tyrosine phosphorylation of Mdm2 by the ErbB-4 intracellular domain fragment

1 reference

12 December 2020

Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu

1 reference

12 December 2020

Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling

1 reference

12 December 2020

c-erbB-4/HER4: friend or foe?

1 reference

12 December 2020

Presenilin-dependent ErbB4 nuclear signaling regulates the timing of astrogenesis in the developing brain

1 reference

12 December 2020

Specificity within the EGF family/ErbB receptor family signaling network

1 reference

12 December 2020

An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors

1 reference

12 December 2020

EGFR associated expression profiles vary with breast tumor subtype

1 reference

12 December 2020

Presenilin-dependent gamma-secretase processing regulates multiple ERBB4/HER4 activities.

1 reference

12 December 2020

Identification of the scaramanga gene implicates Neuregulin3 in mammary gland specification

1 reference

12 December 2020

ErbB4 signaling in the mammary gland is required for lobuloalveolar development and Stat5 activation during lactation

1 reference

12 December 2020

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

12 December 2020

Mammary ductal morphogenesis requires paracrine activation of stromal EGFR via ADAM17-dependent shedding of epithelial amphiregulin

1 reference

12 December 2020

MUC1 is a novel regulator of ErbB1 receptor trafficking

1 reference

12 December 2020

gamma -Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase

1 reference

12 December 2020

Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis: distribution of homo- and heterodimers depends on relative HER2 levels

1 reference

12 December 2020

Gene targeting of ErbB3 using a Cre-mediated unidirectional DNA inversion strategy.

1 reference

12 December 2020

Activation and function of the epidermal growth factor receptor and erbB-2 during mammary gland morphogenesis.

1 reference

12 December 2020

Heregulin-dependent translocation and hyperphosphorylation of ErbB-2.

1 reference

12 December 2020

Signaling through the stromal epidermal growth factor receptor is necessary for mammary ductal development.

1 reference

12 December 2020

Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactation

1 reference

12 December 2020

Neural and mammary gland defects in ErbB4 knockout mice genetically rescued from embryonic lethality

1 reference

12 December 2020

The role of ErbB3 and its binding partners in breast cancer progression and resistance to hormone and tyrosine kinase directed therapies

1 reference

12 December 2020

Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer

1 reference

12 December 2020

Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma

1 reference

12 December 2020

Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast

1 reference

12 December 2020

The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins

1 reference

12 December 2020

Co-targeting insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer

1 reference

12 December 2020

ERBB receptors and cancer: the complexity of targeted inhibitors

1 reference

12 December 2020

Mechanism of activation and inhibition of the HER4/ErbB4 kinase

1 reference

12 December 2020

EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival.

1 reference

12 December 2020

Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network

1 reference

12 December 2020

EGFR signal transactivation in cancer cells

1 reference

12 December 2020

Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells

1 reference

12 December 2020

Untangling the ErbB signalling network

1 reference

12 December 2020

Heregulin induces in vivo proliferation and differentiation of mammary epithelium into secretory lobuloalveoli

1 reference

12 December 2020

ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer

1 reference

12 December 2020

Impaired differentiation and lactational failure of Erbb4-deficient mammary glands identify ERBB4 as an obligate mediator of STAT5.

1 reference

12 December 2020

ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis

1 reference

12 December 2020

AKT/PKB signaling: navigating downstream

1 reference

12 December 2020

An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor

1 reference

12 December 2020

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

1 reference

12 December 2020

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

12 December 2020

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

1 reference

12 December 2020

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

1 reference

12 December 2020

Targeted disruption of ErbB2/Neu in the mammary epithelium results in impaired ductal outgrowth

1 reference

12 December 2020

The E3 ligase Aip4/Itch ubiquitinates and targets ErbB-4 for degradation

1 reference

12 December 2020

Muc4/sialomucin complex, the intramembrane ErbB2 ligand, in cancer and epithelia: to protect and to survive

1 reference

12 December 2020

Transphosphorylation of kinase-dead HER3 and breast cancer progression: a new standpoint or an old concept revisited?

1 reference

12 December 2020

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

1 reference

12 December 2020

The intracellular domain of ErbB4 induces differentiation of mammary epithelial cells

1 reference

12 December 2020

Gene copy numbers of HER family in breast cancer

1 reference

12 December 2020

ErbB2 is required for ductal morphogenesis of the mammary gland

1 reference

12 December 2020

ErbB-4 s80 intracellular domain abrogates ETO2-dependent transcriptional repression

1 reference

12 December 2020

The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies

1 reference

12 December 2020

Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development

1 reference

12 December 2020

Heregulin stimulates mitogenesis and phosphatidylinositol 3-kinase in mouse fibroblasts transfected with erbB2/neu and erbB3.

1 reference

12 December 2020

Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells

1 reference

12 December 2020

The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells

1 reference

12 December 2020

A new mutational AKTivation in the PI3K pathway

1 reference

12 December 2020

Prognostic value of ERBB family mRNA expression in breast carcinomas

1 reference

12 December 2020

Dynamic expression and activation of ERBB receptors in the developing mouse mammary gland.

1 reference

12 December 2020

Type 1 growth factor receptor expression in node positive breast cancer: adverse prognostic significance of c-erbB-4

1 reference

12 December 2020

Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells

1 reference

12 December 2020

Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions

1 reference

12 December 2020

Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells.

1 reference

12 December 2020

ErbBs in mammary development

1 reference

12 December 2020

Activation of ErbB4 by the bifunctional epidermal growth factor family hormone epiregulin is regulated by ErbB2

1 reference

12 December 2020

10.1007/S10911-008-9083-7

Identifiers

DOI

1 reference

2 July 2019

PMCID

6590701

1 reference

2 July 2019

PubMed ID

18454306

1 reference

2 July 2019